Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/2NI1Ok9
via IFTTT